SCHEMBL2857641

SCHEMBL2857641

COc1ccc(Cn2c(=O)c3c(N)n(-c4cc(OC)c(C)cc4C)nc3c3ccc(OC(C)C)cc32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 6/20 0.38
PDE1A P54750 5/20 0.38
PDE1C Q14123 5/20 0.38
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 2/20 0.36
TP53 P04637 1/20 0.36
PLA2G10 O15496 1/20 0.36
P2RX7 Q99572 2/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
PLA2G2A P14555 2/20 0.35
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861122 0.92 PDE1A (0.39) PDE1BPDE1APDE1CMAPTMEN1
SCHEMBL2858941 0.91 GAA (0.38) PDE1BPDE1APDE1CMAPTMEN1
SCHEMBL2862709 0.89 RXFP1 (0.42) PDE1BPDE1APDE1CMAPTPOLB
SCHEMBL2866691 0.89 PIK3R1 (0.40) PDE1BPDE1APDE1CMAPTMEN1
SCHEMBL2862341 0.87 PDE1B (0.40) PDE1BPDE1APDE1CMAPTGAA
SCHEMBL2862981 0.87 PLA2G10 (0.39) PDE1BPDE1APDE1CMEN1GAA
SCHEMBL2865416 0.85 S1PR3 (0.41) PDE1BPDE1APDE1CMAPTMEN1
SCHEMBL2866734 0.85 MAPT (0.42) PDE1BPDE1APDE1CMAPTMEN1
SCHEMBL2863040 0.83 MAPT (0.43) PDE1BPDE1APDE1CMAPTMEN1
SCHEMBL2870221 0.83 PDE1B (0.38) PDE1BPDE1APDE1CMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 PDE1B 2570/4885PDE1A 3138/4885PDE1C 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.